Medical treatment of cataract

@article{Toh2007MedicalTO,
  title={Medical treatment of cataract},
  author={Tze'yo Toh and J R Morton and J P Coxon and Mark J. Elder},
  journal={Clinical \& Experimental Ophthalmology},
  year={2007},
  volume={35}
}
The incidence of cataract continues to increase with the ageing of the population. Surgical treatment with phacoemulsification and intraocular lens implantation remains the only proven treatment. This, however, is associated with significant cost and is not readily available especially in the developing countries where the prevalence of cataract is the highest. Medical treatment of cataract is therefore a highly desired alternative. Since the last major review of medical treatment of cataract… 
View on Wiley
ncbi.nlm.nih.gov
39 Citations
Highly Influential Citations
2
Background Citations
11
Methods Citations
1
Results Citations
1

39 Citations

Citation Type

Citation Type

A perspective of contemporary cataract surgery: the most common surgical procedure in the world
TLDR
Clinicians and scientists in New Zealand / Aotearoa have contributed significantly to the global knowledge of cataract surgery, including aspects of indications for surgery, assessment and use of specialised intraocular lenses, effect of surgical techniques on corneal structure and performance, training ofCataract surgeons, intraoperative and post-operative complications.
Age ‑ related vision loss: cataract
TLDR
This review addresses issues regarding age-related cataract and its management, with a focus on those issues important to the nonophthalmologist, including the pathogenesis of cataracts, common referral criteria and basic aspects of surgical management.
Medicinal Plants and Natural Products Used in Cataract Management
TLDR
This review documented medicinal plants and plant-based natural products used for cataract treatment worldwide, which are gathered from available ethnopharmacological/ethnobotanical data, and summarized the plants/phytoconstituents that are evaluated in different models of cataracts.
Aging Disorders of the Eye: Challenges and Approaches for Their Treatment
TLDR
The proportion of the global population aged 60 years and over is steadily increasing and projected to increase to almost 30 % in 2050, and there are added difficulties due to multiple diseases and health problems, the several medications being taken together and the physical and psychological difficulties.
Use of cataract surgery in urban Beijing: a post screening follow-up of the elderly with visual impairment due to age-related cataract.
Effect of oral antioxidants on the progression of canine senile cataracts: a retrospective study
TLDR
Although there was no significant delaying effect of oral antioxidants on incipient cataract progression, antioxidants could be used to delay the progression of senile immature cataracts through retrospective analysis.
Mutations and mechanisms in congenital and age-related cataracts.
Biology of Inherited Cataracts and Opportunities for Treatment.
TLDR
New therapeutic approaches to age-related cataracts use chemical chaperones to solubilize HMW aggregates, while attempts are being made to regenerate lenses using endogenous stem cells to treat congenital cataract.
Ocular Health, Vision, and a Healthy Diet
PLA-PEG Micelles Loaded with a Classic Vasodilator for Oxidative Cataract Prevention.
TLDR
NFP-loaded PLA-PEG micelles not only showed satisfactory biocompatibility and bioavailability, but also efficiently improved the anticataract ability through the inhibition of extracellular calcium ions influx in a new insight into the development of cataract treatment.
...
...

References

SHOWING 1-10 OF 88 REFERENCES
Can cataract be prevented?
TLDR
Positive results have been achieved in vitro, and in the prevention of diabetic cataract in rats, as well as the identification of an association with a protective effect against cataracts in human patients, and other anti-cataract agents are also being investigated.
Medical treatment of cataract
TLDR
In formulating an approach to the medical treatment of cataract, it is fruitful to consider factors which render the lens transparent and the influences which can lead to opacity.
Efficacy of N-Acetylcarnosine in the Treatment of Cataracts
TLDR
Topical NAC shows potential for the treatment and prevention of cataracts in patients with cataract with minimum to advanced opacification in various lens layers and the apparent benefits of treatment were sustained after 24 months’ treatment.
Lipid Peroxidation and Cataracts
TLDR
The role of free radical-induced lipid oxidation in the development of cataracts has been identified and N-acetylcarnosine (as the ophthalmic drug Can-C™), has been found to be suitable for the nonsurgical prevention and treatment of age-related cataract.
Incremental cost-effectiveness of initial cataract surgery.
Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes.
TLDR
N-acetylcarnosine (as the ophthalmic drug Can-C), has been found to be suitable for the nonsurgical prevention and treatment of age-related cataracts and in a recent clinical trial it was shown to produce an effective, safe and long-term improvement in sight.
Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts.
TLDR
Although the results of preliminary studies have suggested that the drug may be useful for delaying the progression of cataract, further clinical studies using proven objective methods are required to fully establish its value in the management of this condition and its long term tolerability.
Global cost-effectiveness of cataract surgery.
Cost-utility analysis of cataract surgery in the second eye.
Bendazac lysine in selected types of human senile cataract. A long-term double-masked placebo-controlled clinical trial with multilinear densitometric image analysis of Scheimpflug photographs.
TLDR
It is shown that the increase in light scattering over time, i.e. the progression of cataract, is less in bendazac lysine-treated patients than in those treated with placebo.
...
...